Trevi Therapeutics (TRVI) Net Cash Flow Growth (3y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 32.17% |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | 36.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.28% |
| Dec 31, 2025 | 11.08% |
| Sep 30, 2025 | -50.92% |
| Jun 30, 2025 | 25.18% |
| Mar 31, 2025 | -24.03% |
| Dec 31, 2024 | 33.93% |
| Sep 30, 2024 | 34.53% |
| Jun 30, 2024 | 45.17% |
| Mar 31, 2024 | -75.63% |
| Dec 31, 2023 | 40.54% |
| Sep 30, 2023 | 10.25% |
| Jun 30, 2023 | 31.02% |
| Mar 31, 2023 | 41.45% |
| Dec 31, 2022 | -105.71% |
| Sep 30, 2022 | 94.16% |
| Jun 30, 2022 | -5.19% |
| Mar 31, 2022 | -49.53% |
| Dec 31, 2021 | 47.15% |
| Sep 30, 2021 | -45.77% |
| Jun 30, 2021 | 16.70% |
| Mar 31, 2021 | 17.28% |